In December 2014, the Food and Drug Administration (FDA) approved liraglutide for weight loss, and semaglutide was approved for diabetes in 2017 and obesity in 2021, opening a new era of obesity treatment
The difference can be very meaningfulseveral percentage points higher for the Rx trend. In some cases, overall prescription drug trend may jump by as much as 15% when GLP-1 medications are included, making them a dominant contributor to pharmacy cost growth
Some days its gone completely
A clinical trial investigated the effect of 8-week metformin treatment on aging individuals with mild cognitive impairment (MCI) or early AD, and the results revealed that metformin is associated with improved executive function, companied by improvement in learning/memory and attention [27]
The steep weight loss and significant cardiovascular and metabolic benefits associated with drugs like semaglutide and tirzepatide underlie their rapid rise in popularity